EDIT Earnings Date: Nov 9, 2026 (Estimated) — Editas Medicine, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is EDIT's next earnings date?
Editas Medicine, Inc. (EDIT) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.21 on revenue of $4.5M.
How did EDIT do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Editas Medicine, Inc. posted EPS of -$0.15 versus the -$0.27 estimate, a beat of 46.4%. Revenue was $11.9M against a $2.8M estimate. The stock's 1-day post-earnings move was +5.5%.
How much does EDIT stock move after earnings?
EDIT beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.5% (up or down) in the day after earnings.
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.27 | -0.15 | +46.43% | $11.9M | ✅ Beat | +5.45% | +3.27% | +12.00% |
| 2026-05-05 | Q1 2026 | -0.25 | -0.26 | -4.00% | $2.8M | ❌ Miss | +1.33% | +2.00% | -7.33% |
| 2026-03-09 | Q4 2025 | -0.24 | -0.06 | +75.00% | $24.7M | ✅ Beat | +16.00% | +22.00% | +37.00% |
| 2025-11-10 | Q3 2025 | -0.38 | -0.28 | +26.32% | $7.5M | ✅ Beat | +2.02% | +5.26% | -1.21% |
| 2025-08-12 | Q2 2025 | -0.39 | -0.63 | -61.54% | $3.6M | ❌ Miss | +34.50% | +14.85% | +18.34% |
| 2025-05-12 | Q1 2025 | -0.59 | -0.43 | +27.12% | $4.7M | ✅ Beat | -2.60% | -3.25% | +31.82% |
| 2025-03-05 | Q4 2024 | -0.38 | -0.40 | -5.26% | $30.6M | ❌ Miss | -13.17% | -26.34% | -45.37% |
| 2024-11-04 | Q3 2024 | -0.78 | -0.75 | +3.85% | $61,000 | ✅ Beat | -1.03% | +7.22% | -31.96% |
Showing last 8 quarters.